MULTIPASS: gestion des consentements pour accéder aux données des exploitations dans une chaîne de confiance afin de favoriser l'émergence de nouveaux services pour les agriculteurs

12th EFITA International Conference, Rhode island, GRC, 27-/06/2019 - 29/06/2019International audienceWith the emergence of digital technologies, farms become a relevant source of data to meet the challenges of multi-performance agriculture. Beyond the services provided, access to farmers' data depends on a clear understanding of their use, which must be done in a transparent way. Several codes of conduct at a national or international level push for a voluntary commitment to respect some good practices in the use of agricultural data. To provide a tool and answer farmer's questions on the control of their data and the transparency of the data processing, the partners of the MULTIPASS project, have imagined an interoperable ecosystem of farmer consents management, protecting farmers from no consented uses of their data.Farmers' expectations of such an ecosystem have been expressed during workshops. They want to better identify existing data flows, including actors, data processes, and data clusters. Based on the farmers' expectations, the MULTIPASS project stakeholders have proposed the architecture of an ecosystem integrating two consent management tools as "pilots". This ecosystem should take in charge the interoperability between each consent management tools or with future tools. This solution is based on a shared typology of data and data processes as well as on the specifications of the consent message content. All these elements should be easily accessible to meet the interoperability need of the ecosystem. It is also based on a router, which provides unified access to consent management tools (using API). In particular, it provides the farmer (beneficiary) with an exhaustive view of his/her consents (which can be distributed on several consent management systems), meeting farmers' expectations for transparency. It is also the point where a data provider can check whether the consent required to provide data exists, without needing to know which consent management system is concerned. In this project, the stakeholders want to demonstrate to agricultural professional organizations the benefits and feasibility of a consent management ecosystem. By strengthening the confidence of farmers to share data, the project will allow the emergence of new knowledge and new services

All-solid-state electrochromic reflectance device for emittance modulation in the far-infrared spectral region

All-solid-state electrochromic reflectance devices for thermal emittance modulation were designed for operation in the spectral region from mid- to far-infrared wavelengths (2–40 μm). All device constituent layers were grown by magnetron sputtering. The electrochromic (polycrystalline WO3), ion conductor (Ta2O5), and Li+ ion-storage layer (amorphous WO3), optimized for their infrared (IR) optical thicknesses, are sandwiched between a highly IR reflecting Al mirror, and a 90% IR transmissive Al grid top electrode, thereby meeting the requirements for a reversible Li+ ion insertion electrochromic device to operate within the 300 K blackbody emission range. Multicycle optical switching and emittance modulation is demonstrated. The measured change in emissivity of the device is to 20%

A Controversy That Has Been Tough to Swallow: Is the Treatment of Achalasia Now Digested?

Esophageal achalasia is a rare neurodegenerative disease of the esophagus and the lower esophageal sphincter that presents within a spectrum of disease severity related to progressive pathological changes, most commonly resulting in dysphagia. The pathophysiology of achalasia is still incompletely understood, but recent evidence suggests that degeneration of the postganglionic inhibitory nerves of the myenteric plexus could be due to an infectious or autoimmune mechanism, and nitric oxide is the neurotransmitter affected. Current treatment of achalasia is directed at palliation of symptoms. Therapies include pharmacological therapy, endoscopic injection of botulinum toxin, endoscopic dilation, and surgery. Until the late 1980s, endoscopic dilation was the first line of therapy. The advent of safe and effective minimally invasive surgical techniques in the early 1990s paved the way for the introduction of laparoscopic myotomy. This review will discuss the most up-to-date information regarding the pathophysiology, diagnosis, and treatment of achalasia, including a historical perspective. The laparoscopic Heller myotomy with partial fundoplication performed at an experienced center is currently the first line of therapy because it offers a low complication rate, the most durable symptom relief, and the lowest incidence of postoperative gastroesophageal reflux

Vortex pinning in an irradiated Bi-2212 single crystal: What about the screening of the transverse magnetic field?

Magneto-transport measurements I-V have been recorded for B=300G at both low and high temperature in Bi-2212 single crystals irradiated along the c-axis. Pinning properties have been studied versus the temperature T, and the angle $\Theta$ between B and the columnar defects (CD's). We show that I$_{c}$ decreases as t=T/T$_{c}$ is lowered below 0.3. This result suggests that the rigidity of the moving vortex system increases as T decreases. The angular dependence of I$_{C}$ confirms that, at low temperature, the pinning is collective as it has already been shown. More, the fact that the vortex penetration always take place parallel to the c-axis of the sample evidences an intrinsic infinite tilt modulus C44. At high temperature, C44 is finite and the localization of the discrete vortices takes place over different column sites. Key words. Columnar defects - Peak effect - Plasticity - Critical current – Decoupling

Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: a randomized phase III study

International audienceBACKGROUND:A minority of early breast cancer (EBC) patients treated with adjuvant or neoadjuvant chemotherapy have sufficient baseline vitamin D (vitD) level. This randomized phase III study assessed the safety and efficacy of a tailored, high-dose, oral vitD supplementation in restoring a normal 25-hydroxy vitD (25OHD) level in this population.PATIENTS AND METHODS:Participants received a 6-month conventional (C) vitD and calcium supplementation or a 6-month high-dose oral vitD regimen tailored on the deficiency (T) and a conventional calcium supplementation. The primary end point was the 6-month percentage of 25OHD serum level normalization.RESULTS:A total of 215 patients including 197 patients with vitD deficiency were recruited, and 195 patients were randomized (T, 100; C, 95). Compliance to the daily oral supplementation was 68.4% and 67% in the C and T arms, respectively. Discontinuous high-dose vitD compliance appeared higher in the T arm (77%). At 6 months, more patients presented with a normalized vitD level in the T arm (30% versus 12.6%; P = 0.003). Supplementation was well tolerated, and no significant difference in the treatment-related toxicity between the two arms was reported. Fifty-two patients without vitD normalization from the C arm switched to the T arm after 6 months. At 12 months, 44% of these patients achieved vitD normalization.CONCLUSION:A tailored high-dose oral vitD supplementation safely allows a higher percentage of the serum 25OHD level normalization compared with a conventional regimen in chemotherapy-treated EBC patients. As compliance to a daily oral supplementation remains poor in this setting, an adaptation of the treatment schedule is warranted.CLINICAL TRIAL NUMBER:NCT01480869